Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
An Open-label, Prospective, Randomized, Phase III, International Multicenter Clinical Study to Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-Ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
Shandong Cancer Hospital and Institute
335 participants
Jan 5, 2026
INTERVENTIONAL
Conditions
Summary
This is an open-label, prospective, randomized, Phase III, international multicenter clinical study to compare radiotherapy plus nimotuzumab versus radiotherapy alone in platinum-ineligible patients with locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC),
Eligibility
Inclusion Criteria22
- Eligible subjects must meet all of the following:
- Age ≥18 years.
- Histologically confirmed stage III-IVB (AJCC 8th edition) head and neck squamous cell carcinoma (including cancers of the oral cavity, oropharynx, hypopharynx, and larynx).
- Unsuitable for surgical treatment (defined as: due to patient condition or tumor factors \[T3-4 N0-3 M0, or T1-2 N2-3 M0\] or medical reasons, surgery is not feasible; or an R0 resection is not achievable).
- Suitable for definitive radiotherapy with curative intent.
- At least one of the following reasons for being unsuitable for cisplatin-based chemotherapy:
- Age ≥65 years and, in the investigator's judgment, unable to tolerate chemotherapy;
- ECOG Performance Status \>2 (if this criterion is met, the ECOG criterion listed below may be waived);
- Renal dysfunction: creatinine clearance (CrCl) \<50 mL/min (Cockcroft-Gault) (if this criterion is met, the renal function criterion listed below may be waived);
- Severe tinnitus or hearing loss (requires a hearing aid or audiometry shows ≥25 dB loss at two consecutive frequencies);
- Peripheral neuropathy \> Grade 1;
- Inability to receive intravenous hydration (e.g., due to cardiac dysfunction) or other comorbidities, per investigator's judgment.
- Provide tumor tissue, whenever possible, for EGFR testing; for oropharyngeal cancer, provide tissue for HPV/p16 testing if feasible (no need to retest if previously tested).
- ECOG Performance Status 0-1 (or Karnofsky Performance Status ≥80).
- At least one measurable lesion per RECIST 1.1.
- Expected survival ≥6 months.
- Adequate hematologic function: WBC ≥4×10\^9/L; absolute neutrophil count ≥1.5×10\^9/L; platelets ≥100×10\^9/L; hemoglobin ≥90 g/L.
- Adequate renal function: serum creatinine ≤1.5×ULN or CrCl ≥60 mL/min (Cockcroft-Gault):
- Female CrCl = (140 - age) × weight (kg) × 0.85 / (72 × S\_cr \[mg/dL\])
- Male CrCl = (140 - age) × weight (kg) × 1.00 / (72 × S\_cr \[mg/dL\])
- Adequate liver function: total bilirubin ≤1.5×ULN; AST ≤2.5×ULN; ALT ≤2.5×ULN.
- Voluntary participation: signed written informed consent and ability to comply with visits and procedures.
Exclusion Criteria12
- Any of the following excludes enrollment:
- Receipt of a PD-1 inhibitor, EGFR monoclonal antibody, EGFR-TKI, or anti-angiogenic agent within 4 weeks prior to enrollment.
- Participation in another interventional clinical trial within 30 days prior to screening.
- History of other malignancy (except cured basal cell carcinoma of the skin).
- History of primary immunodeficiency.
- Uncontrolled comorbid conditions (e.g., congestive heart failure, severe pulmonary disease, severe liver disease, psychiatric illness).
- Known HIV infection, or active viral hepatitis or active tuberculosis.
- Major surgery within 90 days before first study treatment, or planned surgery during the study.
- Known allergy to nimotuzumab or its excipients.
- Deemed unsuitable to participate by the investigator.
- Unwilling or unable to sign informed consent.
- Receipt of a live vaccine within 30 days before first dose.
Interventions
Treatment regimen: Nimotuzumab(Experimental Group): nimotuzumab injection 200 mg IV once weekly (QW) for 7 weeks (concurrent with radiotherapy).
Treatment regimen: Radiotherapy (both groups): intensity-modulated technique (photon IMRT or proton IMPT); total dose 70 Gy (2.0 Gy per fraction, 35 fractions), 5 fractions per week.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07333274